Nanotechnology-Based Nucleic Acid Vaccines for Treatment of Ovarian Cancer

Pharm Res. 2023 Jan;40(1):123-144. doi: 10.1007/s11095-022-03434-4. Epub 2022 Nov 14.

Abstract

Anticancer vaccines represent a promising approach for effective treatment of cancer and along with recent advantages of nucleic acid-based vaccines for other diseases form a prospective and potentially efficacious direction of the research, development and clinical applications. Despite the ongoing several clinical trials of mRNA vaccines for the treatment of various types of cancer, to-date no cancer vaccines were approved by the US Food and Drug Administration. The present review analyzes and summarizes major approaches for treating of different forms of ovarian cancer including mRNA-based vaccines as well as nanotechnology-based approaches for their delivery.

Keywords: cancer; mRNA; nanoparticles; ovarian; vaccine.

Publication types

  • Review

MeSH terms

  • Cancer Vaccines* / therapeutic use
  • Female
  • Humans
  • Nanoparticles* / therapeutic use
  • Nanotechnology
  • Nucleic Acid-Based Vaccines
  • Ovarian Neoplasms* / drug therapy
  • Ovarian Neoplasms* / therapy
  • Prospective Studies
  • Vaccines*

Substances

  • Nucleic Acid-Based Vaccines
  • Vaccines
  • Cancer Vaccines